Introduction
============

Medullary breast carcinomas (MBCs) represent 2% of all invasive breast carcinomas, and although these tumors show aggressive pathological features they are often associated with a more favorable outcome. They are defined by an association of five morphological features \[[@B1]\]: a predominantly syncytial growth pattern, a circumscribed border, a moderate to marked lymphoplasmacytic infiltrate, poorly differentiated nuclear grade with high mitotic rate, and the absence of glandular features or any *in situ*component. Despite these defined morphological features, reproducibility of diagnosis is only moderate. Therefore, more specific and new diagnostic criteria such as genetic features would be very helpful. Gene expression profile analysis classifies breast carcinomas into five groups: luminal--epithelial/estrogen receptor (ER)-positive A and B, basal-like, ERBB2, and normal-like carcinomas \[[@B2]-[@B5]\]. The basal-like group of tumors was associated with a poorer outcome than that of luminal tumors \[[@B5]\]. Moreover, basal-like carcinomas (BLCs) were characterized by a specific immunophenotype that was negative for ER, progesterone receptor (PR) and ERBB2, and positive for cytokeratin (KRT) type 5/6, KRT 14 or KRT 17, epidermal growth factor receptor (EGFR) and KIT; \[[@B5],[@B6]\] they were also associated with *TP53*mutations \[[@B3]\]. We have previously shown that MBCs were associated with a very high rate of *TP53*mutations \[[@B7]\]. Recently MBCs were found to present a basal-like/myoepithelial phenotype \[[@B8],[@B9]\] with a specific gene overexpression profile \[[@B10]\]. We and others have demonstrated that MBCs have a favorable outcome despite the aggressive pathological features at presentation \[[@B11]-[@B13]\] and unlike basal-like tumors \[[@B5]\]. This favorable outcome may be explained in part by the radiosensitivity and chemosensitivity of MBCs \[[@B11]\]. To address the biological differences between MBCs and BLCs, we performed an immunophenotype analysis, a *TP53*sequence analysis and large-scale analysis by array comparative genomic hybridization (aCGH) on a series of 33 MBCs and compared their immunoprofiles and genetic alterations with those of a group of 26 non-medullary BLCs. These analyses reveal that MBCs have distinct specificities, both at the immunophenotypic level, including more frequent cytokeratin 5/6 expression, and at the genomic level with a high level of chromosome gains and losses, recurrent 10p, 9p and 16q gains and 4p losses, and 1q, 8q, 10p and 12p amplicons.

Materials and methods
=====================

Patients and tumors
-------------------

We studied tumors from two groups of patients. Experiments were performed in accordance with Bioethics Law no. 2004-800 and the Ethics Charter from the National Institute of Cancer (INCa). The first group consisted of 33 MBCs; the second group consisted of 26 non-medullary BLCs.

We initially selected 42 patients with MBCs from our files, prospectively registered in our institutions (32 cases from Institut Curie and 10 cases from Institut Bergonié) for which a representative paraffin-block sample and a frozen sample were both available. Samples with less than 50% of tumor cells were excluded from the study. A retrospective pathological review of all cases was performed by four breast pathologists (AVS, BSZ, GMG and IdM) in accordance with Ridolfi\'s criteria \[[@B1]\], namely pushing margins, syncytial growth pattern without any glandular structures, high nuclear grade with a vesicular chromatin and a high mitotic activity, a dense lymphoplasmacytic infiltrate and no associated ductal carcinoma *in situ*. We have considered here that the three major morphological traits that most clearly distinguish MBCs from BLCs were as follows: first, the presence of large nuclei, irregular in shape, with vesicular chromatin and large eosinophilic nucleoli; second, cells organized in solid syncytial sheets seven to eight cells thick, in a ribbon-like structure; and third, the interspersing of the ribbon-like structure with a stroma composed of a dense lymphoplasmacytic infiltrate with no myofibroblasts and no fibrosis. Seven cases were excluded after pathological review and two for insufficient aCGH quality (see Additional file 1); 33 patients with MBCs were eventually available for genetic analysis.

The second group of tumors were from 26 patients with BLCs. These cases were selected from our files among ER^-^PR^-^ERBB2^-^invasive ductal carcinomas, according to their basal immunophenotype, defined as follows: ER^-^PR^-^ERBB2^-^with the expression of at least one of the following markers: basal-myoepithelial KRT 5/6, KRT14, EGFR and KIT.

DNA and RNA extraction
----------------------

DNA was extracted from frozen tumor samples with the use of a standard phenol/chloroform procedure. A frozen tissue section was performed on the remaining frozen fragments to evaluate tumor cellularity. All tumors analyzed presented more than 50% of tumor cells on the control tissue section. Total RNA was extracted from frozen tumor samples with the RNeasy^®^kit (Qiagen, Courtaboeuf, France), then the RNA clean up kit (Macherey Nagel, France), in accordance with the manufacturers\' instructions. The quality of each RNA sample was measured with an Agilent 2100 bioanalyzer. The quantity of RNA was measured by spectrophotometry at 260 nm.

Immunohistochemistry
--------------------

Immunostaining was performed on 4 μm tissue sections prepared from a representative sample of the tumor. After rehydration and antigenic retrieval in citrate buffer (10 mM, pH 6.1), tissue sections were stained for ER (clone 6F11, 1/200 dilution; Novocastra, Newcastle Upon Tyne, UK), PR (clone 1A6, 1/200 dilution; Novocastra), ERBB2 (clone CB11, 1/1,000 dilution; Novocastra), EGFR (HER1; clone 31G7, 1/40 dilution; Zymed), CD117 (an epitope of KIT, polyclonal, 1/100 dilution; Dako A/S, Glostrup, Denmark), TP53 (clone DO7, 1/50 dilution; Dako), KRT 5/6 (clone D5/16B4, 1/50 dilution; Dako), KRT 8/18 (clone DC10, 1/100 dilution; Zymed) and KRT 14 (clone LL002, prediluted; Biogenex, San Ramon, CA, USA). Staining was conducted with the Vectastain Elite ABC peroxidase mouse IgG kit (Vector Laboratories, Burlingame, CA, USA), with diaminobenzidine (Dako) as the chromogen. Positive nuclear staining for ER, PR and TP53 was recorded in accordance with standardized guidelines, using 10% of positive cells as the cutoff for ER, PR and TP53. For ERBB2, only staining of membranes was considered, as defined previously \[[@B14],[@B15]\]. CD117 and KRT 5/6, KRT 14 and KRT 8/18 were scored positive if any (weak or strong) cytoplasmic and/or membranous invasive carcinoma cell staining was observed in accordance with previous published studies \[[@B6],[@B8],[@B16],[@B17]\]. For EGFR, 10% of positive membranous staining was used as the positive cutoff. For each antibody, internal and external controls were included in the experiments.

*TP53*sequencing
----------------

*TP53*was sequenced in accordance with the previously published procedure \[[@B7]\] or directly from DNA. The *TP53*sequence was not assessed for nine cases for which no more RNA or DNA was available after aCGH. In brief, for sequencing from RNA, total RNA was reverse-transcribed in a final volume of 20 μl containing 1× reverse transcriptase buffer, 10 units of RNase inhibitor (Promega, Madison, WI, USA), 10 mM dithiothreitol, 50 units of Superscript II RNase H reverse transcriptase (Life Technology, Inc., Cergy Pontoise, France), 1.5 mM random hexamers (Pharmacia, Uppsala, Sweden) and 1 μg of total RNA. Samples were incubated at 20°C for 10 minutes and at 42°C for 30 minutes; reverse transcriptase was then inactivated by heating at 99°C for 5 minutes and cooling for 5 minutes. For sequencing from DNA, total DNA was amplified with primers specific for exons 4 to 10 (primer sequences are listed in Additional file 1). Purified PCR products were sequenced bidirectionally with the use of Big Dye Terminator chemistry (Applied Biosystems, Foster City, CA, USA) with an ABI Prism 3700 DNA Analyzer (Applied Biosystems, Foster City, CA, USA). The central part of the *TP53*gene (amplified from cDNA between exons 4 and 10, namely codons 42 to 374) was sequenced for all samples.

Array CGH
---------

The array used contains 3,261 bacterial artificial chromosome (BAC) and P1-derived artificial chromosome (PAC) DNAs, as described previously \[[@B18]\]. All BACs and PACs were verified by end sequencing before spotting, and their positions on the genome have been determined. In brief, after digestion with *Dpn*II (Ozyme, Saint Quentin en Yvelines, France) and column purification (Qiagen PCR Purification Kit; Qiagen), 1.5 μg of tumor DNA and 1.5 μg of normal male DNA were labeled using the BioPrime DNA Labeling System Kit (Invitrogen, Cergy-Pontoise, France), with Cy5dCTP or Cy3-dCTP (Amersham, Uppsala, Sweden), respectively. Labeled tumor and reference DNAs were mixed and precipitated together with 225 μg of human Cot-1 DNA (Invitrogen), resuspended in 65 μl of hybridization buffer (50% formamide, 40 mM NaH~2~PO~4~, 0.1% SDS, 10% dextran sulfate, 2 × standard saline citrate (SSC), Denhardt\'s solution), denatured, prehybridized for 90 minutes at 37°C and hybridized on treated microarray slides. After 24 hours of hybridization at 37°C in a humidity chamber and appropriate washing, slides were scanned with a GenePix 4000B scanner (Axon Instruments Inc., Union City, CA, USA) and analyzed with GenePix Pro 5.1 image analysis software, which defined the spots and determined the median intensities for the Cy3 and Cy5 signals of each BAC clone.

Analysis of aCGH data
---------------------

Data analysis was based on the normalized ratios of Cy5/Cy3 signals observed for each BAC clone \[[@B19]\] that previously passed the flag assessment procedure (see Additional file 2). For autosomal chromosomes, the loss of a given locus was defined by a ratio less than or equal to 0.8, a gain was defined by a ratio greater than or equal to 1.2 and less than 2.0, and an amplicon was defined by a ratio greater than or equal to 2.0. For X chromosomes, a loss was defined by a ratio less than or equal to 1.2, a gain was defined by a ratio greater than or equal to 1.7, and an amplicon was defined by a ratio greater than or equal to 2.5. Whenever a statistical hypothesis concerning the levels of the ratios was tested, the hypothesis was considered to be rejected for *p*values less than or equal to 0.05. Whenever *p*values were adjusted for multiple hypothesis testing, the false discovery rate using the Benjamini--Hochberg procedure was applied (R-Multitest package).

Data analysis was performed with two complementary approaches: a descriptive approach and a statistical approach. For the descriptive approach, the frequency of BAC locus gains, losses and amplicons in the two groups of tumors was evaluated to identify genomic regions that could distinguish MBC tumors from BLC tumors. For a given tumor, a region of gain or loss was defined as a set of at least two consecutive BAC loci meeting the gain and loss criteria described above. A region of gain or loss was considered as recurrent when it was observed in at least 20% of tumors. The median frequency was calculated for each region defined previously, to determine the most recurrent alterations. The regions of gains and losses were compared between the two groups by a Fisher exact test, BAC locus by BAC locus (*p*values were not adjusted for multiple tests). A region was considered to be significantly different between the two groups when the majority of the loci in the region presented *p*values less than 0.05.

For analysis of amplicons, the identification criteria were BAC loci consisting of at least one clone with a ratio greater than or equal to 2.0 in one tumor. Finally, a between-group comparison of the mean ratios of each BAC loci in the two groups of tumors was performed; ratios were log~2~transformed, the normal distribution of ratios in the two groups was tested by the Shapiro--France test (R-Nortest package), comparisons were performed with a Welch *T*test and the hypothesis of no difference between the two groups was rejected when the Benjamini--Hochberg false discovery rate, calculated over the 3,264 BAC loci analyzed, was less than or equal to 5%.

For the unsupervised statistical approach, hierarchical clustering was performed to define tumor groups with no *a priori*biological knowledge (see Additional file 3). Its robustness was tested by a resampling approach (see Additional file 3). The enrichment of the groups in BLC and MBC tumors was then tested (Welch *T*test), and genomic regions able to discriminate between the two groups were determined.

Fluorescence *in situ*hybridization (FISH) experiments
------------------------------------------------------

To verify the most recurrent gains observed on the aCGH results, FISH analysis was performed on representative frozen samples of four MBCs that demonstrated 10p gains on aCGH, and four BLCs without 10p gains. Frozen tissue sections 4 μm thick were prepared and fixed for 10 minutes in a mixture of ethanol/acetic acid (2:1, by volume). A probe was selected within the regions of gains on the 10p chromosome that differentiated MBC from BLC clusters (TelVysion Spectrum Green 10p from Vysis-chr10: 328,262 to 328,575, and BAC clone g1int953-chr10: 22,497,751 to 22,668,197) and a BAC clone associated with a normal ratio in every case (g1int978-chr10: 50,248,127 to 50,413,107) as control. The BAC DNAs were extracted in accordance with standard procedures. The DNAs were then labeled by nick translation using the BioNick Labeling Kit (BioNick Labeling System; Invitrogen) and the following fluorescent nucleotides: Texas red-dUTP (NEN, Paris, France) for g1int953, and Cy3-dUTP (Amersham, Orsay, France) for g1int978. Each 10p probe was pooled and co-precipitated with the control probe and with an excess of human Cot1 DNA. Denaturation of the probes was performed at 94°C for 10 minutes; the tissue sections were denatured in formamide and 2 × SSC at 72°C for 2 minutes. The probes were then hybridized on the tissue section under a coverslip. Slides were incubated overnight at 37°C in humid chambers, then washed briefly in 1 × SSC for 5 minutes at 20°C and for 5 minutes at 72°C. Finally, slides were counterstained with 4,6-diamidino-2-phenylindole (Vector Laboratories). Images were captured with an Axioplan 2 microscope (Zeiss, Le Pecq, France) with appropriate filters and a Quantix camera (Photometrics, Tucson, AZ, USA) using SmartCapture software (Digital Scientific, Cambridge, UK). Images of an average of 30 nuclei per case were taken and the number of signals for each probe was counted. The mean number of copies of each locus was then determined and compared with the control locus.

Results
=======

Clinical characteristics of patients
------------------------------------

Because several studies have shown a higher incidence of MBCs in young patients, in particular in a *BRCA1*context, we compared the ages of the two groups of patients (MBC group: median 53.5 years; range 34 to 76 years; BLC group: median 60 years; range 37 to 82 years; Table [1](#T1){ref-type="table"}). The age tended to be younger in MBCs, but the difference was not significant (*p*= 0.072, Wilcoxon rank test). Other clinical characteristics were also noted. The clinical stage was T1 for 14 patients with MBC and 6 with BLC, T2 for 15 patients with MBC and 19 with BLC, T3 for 2 patients with MBC and 1 with BLC, N0 for 24 patients with MBC and 18 with BLC, and N1 for 7 patients with MBC and 8 with BLC (clinical stage was not determined for 2 patients with MBC). All MBCs were of grade III; in comparison, 19 BLCs were of grade III and seven were of grade II (*p*= 0.0056, χ^2^test).

*TP53*mutations
---------------

We have previously reported that *TP53*mutations were a genetic trait of MBCs \[[@B7]\], and a high rate of such mutations has been found in BLCs \[[@B3]\]. We therefore assessed the *TP53*sequences in 26 of the 33 MBCs and 24 of the 26 BLCs (Table [1](#T1){ref-type="table"}). A mutation in *TP53*was found in 20 of the 26 MBCs (77%); 16 of these were associated with intense TP53 immunolabeling of tumor cell nuclei (16/20 mutations; Table [2](#T2){ref-type="table"}). There was a *TP53*mutation in 20 of the 24 BLCs sequenced (83%), including five of the seven grade II tumors. In the BLCs, TP53 immunolabeling was concordant with *TP53*mutation status in all cases (100% of mutated cases). No significant difference in *TP53*status was observed between MBCs and BLCs (*p*\> 0.05).

Comparative immunophenotypes of MBCs and BLCs
---------------------------------------------

To address the question of whether MBCs and BLCs present any immunophenotypic difference, we analysed the status of markers that contribute to the definition of a basal-like immunophenotype, namely ER, PR, ERBB2, KRT 5/6, KRT 14 and KRT 8/18 in the two groups (Table [2](#T2){ref-type="table"}). We observed that all tumors from the MBCs group and the selected BLCs tumors were negative for ER, PR and ERBB2. However, a comparison of the immunophenotype of the two groups of tumors showed that MBCs were more often positive for KRT5/6 than BLCs (30/32 (94%) versus 14/25 (56%), respectively; *p*= 0.0007). No difference in immunophenotype was observed between MBCs and BLCs for KRT14 (17/31 (55%) versus 18/23 (78%); not significant), TP53 (20/33 (61%) versus 12/25 (48%); not significant), KRT 8/18 (30/32 (94%) versus 19/25 (76%); not significant), EGFR (22/32 (69%) versus 10/22 (45%); not significant) or KIT (19/32 (59%) versus 12/20 (60%); not significant).

Array CGH results
-----------------

To our knowledge, no unique, standardized method for the analysis of aCGH data has yet been published. We therefore decided to analyse our data with two different approaches: the in the first we looked for the regions already known to be amplified in breast carcinogenesis and described the other new ones. We also evaluated the frequency of gains and losses in the two groups. As a second approach, we used unsupervised clustering. The outcomes of these two approaches led us to draw the same conclusions, which suggest that the new BLC entity could gather different genomic subgroups, one being MBC.

The genes most frequently involved in breast carcinogenesis (*MYC*, *CCND1*, *EGFR*and *CCNE*) were very rarely found amplified in the two groups.

In 17 different MBCs (51%), 59 different amplicons, observed in at least one tumor, were found; in 9 different BLCs (35%), 39 different amplicons were observed. Recurrent amplicons were rare (Table [3](#T3){ref-type="table"}; see also Additional file 4).

Amplicons located on chromosomes 1q, 8p, 10p and 12p were within the most frequent regions of gains and were never observed in BLCs. Only amplicons in 8q24, encompassing *MYC*, and in Xq28 were observed in both groups.

The complete list of regions of gains and losses (frequency greater than 20%) in MBCs and BLCs is presented in Additional file 5. The discriminative regions of gains and losses in MBCs and BLCs are listed in Table [4](#T4){ref-type="table"}, and an average of the genomic profiles of BLCs and MBCs are presented in Figure [1](#F1){ref-type="fig"}.

As shown in Table [4](#T4){ref-type="table"}, very discriminative regions of gains were observed on chromosomes 3, 9, 10, and 16 in the MBCs. The highest frequencies of gain were observed at 10p13 (53%) (*p*= 0.018). A discriminative region of loss was observed on chromosome 4p15.2 (34.8%) (*p*= 0.025).

BLCs were associated with fewer rearrangements than MBCs (see Additional file 5). One discriminative region of loss was observed on the X chromosome in BLCs, with a median frequency of 38.5% of cases (*p*= 0.001).

Common regions of gains and losses were observed on chromosomes 1q, 8q and Xq in both groups.

We performed a genome-wide comparison of the mean ratios between the MBC and BLC groups. Comparison of the two groups was performed, BAC locus by BAC locus, with a Welch *T*test. This test identified only four differential BAC loci between the two groups, three of them located in chromosome 10 and one in chromosome 12. Only two of the BAC loci of chromosome 10 (coordinates on chr10: 6,669,591 to 6,856,917 and 7,349,041 to 7,496,158, respectively) constituted a contiguous region of gain observed in the MBC group but not in the BLC group.

With unsupervised clustering (Figure [2](#F2){ref-type="fig"}), three different clusters were identified: cluster 1 composed of 11 BLCs (85%) and 2 MBCs (15%), cluster 2 composed of 6 BLCs (40%) and 9 MBCs (60%), and cluster 3 composed of 9 BLCs (29%) and 22 MBCs (71%). The differences between these clusters were statistically significant (*p*= 0.012). The dendrogram of the tumor ratios in order of genomic coordinates (Figure [2](#F2){ref-type="fig"}) showed that gain of chromosomes 1q and 8q were common to all tumors. Chromosomes 4 and 5 showed a common trend towards loss. Chromosomes 10 and 12 had a different gain profile depending on the tumor cluster (Figure [3](#F3){ref-type="fig"}): BLC-enriched cluster 1 had a flat profile (around the normal), and cluster 2 showed a clear gain of distal 10p. The dendrogram identified two subgroups in cluster 3: the first subgroup showed a marked and wide 10p gain profile (cluster 3-1), while the second subgroup (cluster 3-2) might present a 12p gain profile. The robustness of this clustering has been confirmed by three different multiple resampling approaches: the first testing the resampling of tumors (consensus clustering methodology of Monti and colleagues \[[@B20]\]), the second testing the resampling of clones (Multiscale bootstrap methodology of Suzuki and colleagues \[[@B21]\]), and a double leave-one-out methodology developed in the laboratory, testing the resampling of both tumors and clones (Additional file 3).

A genome-wide comparison of the mean ratios (Welch *T*test) between cluster 1 and cluster 3-1 identified three large discriminative regions of gain encompassing chromosome 10p (Figure [4](#F4){ref-type="fig"}): the first region was from BAC g11E11 (chr10: 3,723,029 to 3,892,793) to BAC g1int932 (chr10: 14,207,506 to 14,350,672) loci, the second was from BAC g1int936 (chr10: 15,897,438 to 16,092,470) to BAC g1int945 (chr10: 22,556,720 to 22,717,956) loci, and the third was from BAC g1int946 (chr10: 22,559,518 to 22,660,196) to BAC g1int961 (chr10: 24,596,826 to 24,767,011) loci. The second and third regions also differentiated cluster 2 from cluster 3-1 significantly. In contrast, a comparison of clusters 1 and 3-2 did not identify any discriminative regions on chromosome 12 or other chromosomes. Although chromosome 12p seemed to be gained in cluster 3-2 (amplicons excluded), the difference between the two clusters was not statistically significant.

DNA FISH results on MBC and BLC tumors
--------------------------------------

We chose to assess whether the 10p gains, observed in 53% of MBCs and discriminant between clusters 1 and 3-1, could be detected by FISH on frozen tissue sections. For this purpose we analyzed four MBCs tumors with a 10p gain and four control BLCs without a 10p gain.

In MBCs, the mean aCGH ratio was 1.8 for the TelVysion SG locus and 1.6 for the g1int 953 locus, for a mean aCGH ratio of 1.0 for the control locus, g1int978. FISH showed mean numbers of 2.7 and 2.4 copies per nucleus for the first two loci, in the presence of 1.6 copies of the g1int978 control locus.

In BLCs, the mean aCGH ratio was 0.9 for the TelVysion SG locus, and 1.0 for the g1int 953 locus, for a mean aCGH ratio of 0.9 for the control locus, g1int978. Mean numbers of 1.1 and 1.0 copies per nucleus were observed by FISH for the first two loci, in the presence of 1.4 copies of the g1int978 control locus (Figure [5](#F5){ref-type="fig"}).

Discussion
==========

Expression profile analyses \[[@B2]-[@B4]\] have categorized invasive breast carcinomas into five groups: luminal A and B, ERBB2^+^/ER^-^, basal-like and normal breast tumors. The basal-like group was subsequently defined, using immunohistochemistry, as being ER^-^PR^-^ERBB2^-^, with tumor cells expressing at least one basal-myoepithelial marker such as KRT 5/6 or KRT 14 in association with EGFR or KIT \[[@B6],[@B8],[@B22]\]. Although some BLCs are associated with a favorable outcome \[[@B23],[@B24]\], most tumors with a basal-like immunophenotype have been recognized to be associated with a poor prognosis \[[@B5],[@B6],[@B8]\]. MBCs have recently been shown to share the basal-like immunophenotype \[[@B9]\], and some morphological traits that have been reported to be specific for BLC with poor prognosis, such as tumor necrosis, a pushing border of invasion, and a stromal lymphocytic infiltrate \[[@B22],[@B25]\], are also observed in MBCs. These phenotypic and immunophenotypic similarities suggest that these two entities have a common biology despite the fact that MBC presents a more favorable outcome \[[@B11],[@B12]\]. In the present study we wished to define the possible phenotypic and genetic differences between MBCs and BLCs with a view to understanding the major differences in clinical outcome between these tumors.

Subtle morphological differences between BLCs and MBCs suggest that MBCs could be associated with a specific biology such as the low expression of smooth muscle α-actin in MBCs, corroborating the absence of myofibroblasts in MBC stroma \[[@B10]\]. In our study, we confirmed that MBCs shared some basal-like immunophenotypic features and are ER^-^PR^-^ERBB2^-^tumors but have some specificities such as a more frequent KRT5/6 staining of the cells than in BLCs. Abd El-Rehim and colleagues also previously observed \[[@B8]\] that MBCs expressed KRT 5/6 but not KRT 14. Tot \[[@B26]\] and Jacquemier and colleagues \[[@B9]\] found lower rates of KRT5/6 positivity (25% and 44.7%, respectively) than in the present study, but Tot used a different antibody from that used in the present study and, in contrast with the present study, Jacquemier and colleagues included medullary carcinomas that were ER positive and PR positive in 10.5% and 51.3% of cases, respectively. These differences could explain the higher rates of KRT5/6 staining observed in our series of MBCs than in previously published reports.

We also observed high rates of *TP53*mutation in the MBC and BLC groups (77% and 83%, respectively). These rates are in agreement with previously reported results for MBCs and BLCs \[[@B3],[@B7]\].

In terms of genetic changes, as described previously by Chin and colleagues \[[@B27]\], in this basal-like spectrum of tumors we found low-level copy-number alterations and infrequent high-level recurrent amplifications. In addition, MBCs seemed to harbor more gains and losses than BLCs. As seven BLCs tumors were of grade II and all MBCs were of grade III, we could not exclude the possibility that this genomic difference could be simply related to grade. However, five of the seven grade II BLCs had a mutation in *TP53*.

As part of the common basal-like spectrum genomic signature, we found that chromosome 8q, including the 8q24 *MYC*region, was frequently gained in MBCs and in BLCs. This result is in agreement with most published data demonstrating that breast carcinomas with *MYC*amplifications were more frequently ER negative \[[@B28]\] or of the medullary type \[[@B29]\]. It has also been reported that *MYC*amplification occurs in younger patients \[[@B30]\]. The same tendency was observed in our MBC series (53.5 years in MBCs compared with 60.0 years in BLCs). Moreover, it has also been shown that *MYC*contributes to tumor progression in *BRCA1*-associated breast cancers and that it was gained or amplified in 53% of cases \[[@B31]\]. In agreement with these data, 3 of the 20 patients with MBC (15%), in whom it was studied, presented a *BRCA1*mutation (data not shown), which is a higher rate than expected (less than 5%). Taken together, these data suggest that MBC oncogenesis, as part of the basal-like spectrum, could occur more frequently in a context of genetic predisposition than other breast carcinoma types.

Our results suggest that, of the recurrent alterations described for *BRCA1*-associated and high-grade carcinomas, some could be specific for the basal-like spectrum of tumors \[[@B23],[@B27],[@B32]-[@B34]\].

In addition, we report the existence of a combination of genetic alterations associated with the MBC phenotype, namely gains of 3q, 9p, 10p and 16q, losses of 4p, and amplicons of 1q, 8p, 10p and 12p. These data document the heterogeneity of the basal-like group of tumors and contribute to the understanding of its carcinogenesis. If confirmed, these alterations would be helpful in improving the relatively poor diagnostic reproducibility for MBCs \[[@B35]\].

Some putative candidate genes linked with oncogenesis, such as *ZMYND11*(*BS69*), *GATA3*, *CCND2*, *TNFRSF1A*and *BCL2L14*, are present within the two amplicons observed in 10p and 12p. These observations are in agreement with a recent MBC gene expression profile study that showed a gene signature specific for MBCs, with genes from the 12p13 region involved in the same pathways \[[@B10]\].

Previous genetic studies have shown that MBCs, like the basal-like tumor spectrum \[[@B27]\] demonstrated a high rate of chromosome imbalances \[[@B36]\] rather than recurrent high-level amplification. This preferential mechanism of oncogenesis has already been described in predisposition-related cancer syndromes \[[@B37]\]. Our study demonstrates that MBCs effectively presented a high number of gains and losses, suggesting a putative alteration within a DNA damage repair process. If confirmed, this hypothesis could lead to an explanation of their higher sensitivity to radiation therapy and their favorable local and regional outcome \[[@B11],[@B12]\]. These features have already been reported for *BRCA1/2*-related tumors \[[@B37],[@B38]\]. It will therefore be extremely interesting in the future to compare the aCGH profiles of our MBCs with those of *BRCA1*-associated carcinomas. It has also been described previously that an upregulation of cyclin E induces a chromosome instability \[[@B39]\]. Cyclin E overexpression described in MBCs \[[@B40]\] and *BRCA1*-associated tumors \[[@B41]\] could therefore participate in the high chromosomal instability of these tumors.

We also observed that losses in Xq were significantly more frequent in BLCs than in MBCs. These findings are in line with previous publications showing that BLCs display chromosome X abnormalities \[[@B42]\]. Further studies must be conducted to analyze whether the genes involved in the X chromosome alterations correspond to genes from the active or inactive X chromosome.

Conclusion
==========

We have refined in depth the molecular characteristics of MBCs. MBCs tumors belong to the ER^-^PR^-^ERBB2^-^group, harboring a basal-like immunophenotype with a higher rate of KRT 5/6 positivity than BLCs. Furthermore, MBCs have genetic alterations in common with BLCs, such as frequent *TP53*mutations, 8q gains or amplification, 1q gains or amplicons, and X amplicons. Nevertheless, we observed that, in addition to a large number of chromosomal alterations, MBCs are characterized by more frequent 10p, 9p, 3q and 16q gains, 4p losses, and 1q, 8p, and 10p and 12p amplicons. Taken together, these data demonstrate that MBCs, although belonging to the spectrum of basal-like tumors, are associated with specific alterations. A better knowledge of the heterogeneity of the basal-like tumor group should be useful in the near future for more appropriate patient management. Furthermore, the new regions that we have defined as being characteristically modified in MBCs should provide insight into the oncogenic features of this particular class of tumors.
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aCGH = array comparative genomic hybridization; BAC = bacterial artificial chromosome; BLC = basal-like carcinoma; ER = estrogen receptor; FISH = fluorescence *in situ*hybridization; KRT = cytokeratin; MBC = medullary breast carcinoma; PAC = P1-derived artificial chromosome; PR = progesterone receptor; SSC = standard saline citrate.
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###### 

Click here for file

###### Additional File 4

A file showing, for each locus of the array, the normalized CGH ratio. Tumor numbers, identical to those in Table [1](#T1){ref-type="table"}, are indicated.

###### 

Click here for file

###### Additional File 5

A file showing all the gains and losses, ordered by chromosomes and by coordinates, observed in more than 20% of a given group. The significantly discriminative regions are highlighted in grey.

###### 

Click here for file
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![Average genome-wide copy number profiles for medullary breast carcinoma (MBC) and basal-like carcinoma (BLC) tumors. Common alterations observed in both the MBC **(a)**and BLC **(b)**groups are gains of 1q, 8q and Xq (black arrows). The most frequent specific alteration of MBCs (10p gains) is indicated by a red arrow. Ordinates: loci ratios, abscissa: order of the loci on chromosomes from 1 to Y.](bcr1666-1){#F1}

![Dendro-heatmaps of the unsupervised clustering by tumors. The standardized copy number log ratio of all autosomal chromosome loci is shown according to a color scale (top). Tumor groups are distinguished with a color code at the bottom of the dendrogram: red, basal-like carcinomas; blue, medullary breast carcinomas.](bcr1666-2){#F2}

![Dendro-heatmaps of chromosomes 10 and 12. Cluster 3-1 shows a more marked gain of the 10p region than in the other clusters. Tumor groups are distinguished with a color code at the bottom of the dendrogram: red, basal-like carcinomas; blue, medullary breast carcinomas.](bcr1666-3){#F3}

![Box plot of the bacterial artificial chromosome (BAC) loci in chromosome 10. The results of the statistical comparison of the mean of ratios between clusters 1 and 3-1 are shown. On this figure, the BAC loci that are significantly different between the two clusters by the Welch *T*test (*p*≤ 0.05, Benjamini--Hochberg corrected for genome-wide multiple test) and that lie outside the calculated fold range in at least one cluster are shown in different colors: red, cluster 1; blue, cluster 3-1. The BAC loci that are not significantly different in terms of *p*value and fold range are shown in grey and white, for cluster 1 and cluster 3-1, respectively. The position of the centromere is shown with a vertical pink dashed line.](bcr1666-4){#F4}

![Confirmation of 10p gains with the use of fluorescence *in situ*hybridization (FISH). FISH analysis of cases 33 (medullary breast carcinoma) and 26 (basal-like carcinoma) with TelVysion SG 10p (probe 1) shown in green, g1int953 in red (probe 2), and control probe g1int978 in yellow (probe 3).](bcr1666-5){#F5}

###### 

Clinical and biological characteristics of patients with MBCs and BLCs

  Case no.   Age (years)   TNM stage   Histoprognostic grade   *TP53*status   
  ---------- ------------- ----------- ----------------------- -------------- ---------------------
  BLC                                                                         
  1          69            T2N0        3                       ex7            G→A/p. Arg 248 Gln
  2          66            T1N0        2                       ex5            G→T/p. Cys 176 Phe
  3          60            T2N0        2                       ex8            G→A/p. Asp 281 Asn
  4          64            T2N0        2                       int6           Splice
  5          51            T2N1a       3                       wt             \-
  6          62            T1N1a       2                       wt             \-
  7          70            T1N0        3                       ex7            G→A/p. Gly 245 Ser
  8          37            T1N0        2                       ex6            C→T/p. Arg 213 STOP
  9          62            T2N0        2                       ex6            T→G/p. Ser 215 Arg
  10         60            T2N1b       3                       ex8            C→T/p. Arg 282 Trp
  11         52            T2N1        3                       ex6            C→T/p. Arg 213 STOP
  12         50            T3N1        3                       ex5            G→A/p. Arg 175 His
  13         79            T2N0        3                       ex5            C→T/p. Ala 159 Val
  14         48            T2N0        3                       ex10           Del codon 333
  15         42            T1N0        3                       ex6            Del codon 196
  16         52            T2N1b       2                       wt             \-
  17         82            T2N0        3                       wt             \-
  18         46            T2N1a       3                       nd             \-
  19         51            T2N0        3                       nd             \-
  20         81            T2N0        3                       ex7            A→G/p. Tyr 236 Cys
  21         n.d.          T2N0        3                       ex6            T→C/p. Ile 195 Thr
  22         40            T1cN0       3                       ex6            T→G/p. Leu 194 Arg
  23         69            T2N0        3                       ex5            G→A/p. Arg 175 His
  24         69            T2N0        3                       ex5            C→A/p. Tyr 126 STOP
  25         55            T2N0        3                       ex6            C→T/p. Arg 213 STOP
  26         77            T2N1        3                       ex7            A→C/p. Thr 253 Pro
  MBC                                                                         
  1          46            T1cN1       3                       ex7            Del codon 241
  2          34            nd          3                       ex7            Del codon 252
  3          46            T2N0        3                       ex5            G→A/p. Arg 175 His
  4          72            T1cN0       3                       ex8            G→A/p. Arg 280 Lys
  5          39            T3N1        3                       wt             \-
  6          53            T2N0        3                       nd             \-
  7          49            T1cN0       3                       nd             \-
  8          49            T1cN0       3                       nd             \-
  9          33            T2N0        3                       nd             \-
  10         63            T2N0        3                       nd             \-
  11         66            T2N0        3                       nd             \-
  12         50            T1cN1a      3                       nd             \-
  13         57            T1cN0       3                       ex7            G→A/p. Arg 248 Gln
  14         68            T2N0        3                       ex6            C→T/p. Arg 213 STOP
  15         61            T2N0        3                       ex6            A→G/p. Tyr 220 Cys
  16         56            T2N0        3                       wt             \-
  17         58            T2N0        3                       ex8            G→A/p. Glu 286 Lys
  18         57            T2N0        3                       ex8            G→A/p. Cys 275 Tyr
  19         62            T2N0        3                       ex7            G→A/p. Arg 248 Gln
  20         35            T1cN0       3                       ex6            A→G/p. His 193 Arg
  21         54            T1cN1       3                       ex7            G→A/p. Cys 242 Tyr
  22         36            T2N1        3                       wt             \-
  23         48            T1cN1       3                       ex6            Ins codon 213
  24         56            T1cN0       3                       ex5            C→A/p. Ala 161 Asp
  25         42            T3N0        3                       ex6            G→A/p. Val 216 Met
  26         43            T2N0        3                       ex10           G→T/p.Glu 339 STOP
  27         66            T1cN0       3                       ex5            Ins codon 125
  28         50            T1cN0       3                       ex5            G→A/p. Arg 175 His
  29         41            T2N0        3                       ex5            T→C/p. Ser 127 Pro
  30         n.d.          n.d.        3                       ex6            A→G/p. Tyr 220 Cys
  31         76            T2N0        3                       wt             \-
  32         72            T1cN1       3                       wt             \-
  33         67            T1cN0       3                       wt             \-

BLC, basal-like carcinoma; MBC, medullary breast carcinoma; n.d., not determined; wt, wild type; del, deletion; ins, insertion; int, intron; ex, exon; p, protein.

###### 

Immunophenotypes of basal-like carcinomas and medullary breast carcinomas

  Marker            Medullary breast carcinomas (*n*= 33)   Basal-like carcinomas (*n*= 26)   *p*
  ---------- ------ --------------------------------------- --------------------------------- --------
  ER         \+     0 (0)                                   0 (0)                             
             \-     33(100)                                 26 (100)                          \-
  PR         \+     0 (0)                                   0 (0)                             
             \-     33(100)                                 26 (100)                          \-
  ERBB2      \+     0 (0)                                   0 (0)                             
             \-     32 (100)                                25 (100)                          \-
             n.d.   1                                       1                                 
  TP 53      \+     20 (61)                                 12 (48)                           
             \-     13 (39)                                 13 (52)                           n.s.
             n.d.   0                                       1                                 
  KRT 5/6    \+     30 (94)                                 14 (56)                           
             \-     2 (6)                                   11 (44)                           0.0004
             n.d.   1                                       1                                 
  KRT 8/18   \+     30 (94)                                 19 (76)                           
             \-     2 (6)                                   6 (24)                            0.06
             n.d.   1                                       1                                 
  KRT 14     \+     17 (55)                                 18 (78)                           
             \-     14 (45)                                 5 (22)                            n.s.
             n.d.   2                                       3                                 
  EGFR       \+     22 (69)                                 10 (45)                           
             \-     10 (31)                                 12 (55)                           0.06
             n.d.   1                                       4                                 
  KIT        \+     19 (59)                                 12 (60)                           
             \-     13 (41)                                 8 (40)                            n.s.
             n.d.   1                                       6                                 

n.d., not determined; n.s., not significant. Numbers in parentheses are percentages.

###### 

Recurrent identical amplicons observed in at least two tumors

  Chromosome        Start position^a^   End position^a^   Candidate genes                                   Maximum ratio   Number of cases   
  ----------------- ------------------- ----------------- ------------------------------------------------- --------------- ----------------- ---
  1q21.2--21.3      148.109             150.70            *SNX27*, *FLG*, *S100*, *LRN*                     2.2             3                 0
  8p11.21           40.01               42.35             *MYST3*, *ANK1*                                   2.9             3                 0
  8q24              122.64              128.80            *MYC*, *KIAA0196*                                 2.3             2                 2
  10p15.3           0.25                1.00              *ZMYND11*                                         2.3             3                 0
  12p13.32--13.33   2.46                4.31              *CCND2*                                           2.8             2                 0
  12p13.2-13.31     5.16                6.37              *TNFRSF1A*, *NTF3*, *LTBR*, *CD9*                 2.7             3                 0
  12p13.2           7.80                11.7              *PRR4*, *Nanog*, *CD69*, *STELLA/DPPA3*, *PHC1*   3.8             3                 0
  12p13.2           11.95               12.11             *ETV6*, *BCL2L14*                                 9.1             3                 0
  Xp11.22           51.21               53.95             *SSX1*, *SSX2*                                    2.8             0                 2
  Xq28              152.66              153.69            *MTCP1*, *TZ*, *TKTL1*, *FLNA*                    2.8             3                 1

MBC, medullary breast carcinoma; BLC, basal-like carcinoma. ^a^UCSC Genome Browser on Human May 2004 Assembly; positions are given in megabases.

###### 

Regions of gains and losses, significantly different between the MBC and BLC groups

  Chromosome   Region        Alteration   Start position (bp)   End position (bp)   MBC   BLC   Median frequency (percentage)   *p*
  ------------ ------------- ------------ --------------------- ------------------- ----- ----- ------------------------------- ---------
  3            3q27          G            159,935,817           163,800,681         G           30.3                            0.049
  4            4p15.2-15.1   L            27,441,218            30,744,383          L           34.8                            0.025
  9            9p24          G            628,053               2,280,507           G           30.3                            0.0146
  9            9p24          G            3,447,196             7,740,086           G           30.3                            0.022
  9            9p13          G            36,830,822            40,205,823          G           31.8                            0.011
  10           10p14-13      G            10,572,971            15,532,695          G           53.0                            0.018
  16           16q24         G            85,913,563            88,552,226          G           25.8                            0.01525
  X            Xq12--13      L            66,582,902            71,458,243                L     38.5                            0.001

MBC, medullary breast carcinoma; BLC, basal-like carcinoma; G, gain; L, loss. Start and end coordinates of the regions are indicated in bp (May 2004 working draft).
